Lexeo Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
LXEO$3.14+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets (unaudited)
Condensed Balance Sheets
(Unaudited, in thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $28,913 | $35,014 |
| Investments | 70,918 | 86,504 |
| Prepaid expenses and other current assets | 5,443 | 4,603 |
| Total current assets | 105,274 | 126,121 |
| Restricted cash | 3,248 | 3,252 |
| Investments | 7,035 | 7,012 |
| Property and equipment, net | 1,045 | 1,028 |
| Lease right-of-use assets - finance, net | 1,380 | 1,460 |
| Lease right-of-use assets - operating | 7,708 | 8,069 |
| Total assets | $125,690 | $146,942 |
| Liabilities and Stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $11,981 | $6,417 |
| Accrued expenses and other current liabilities | 16,195 | 13,759 |
| Current portion of lease liabilities - finance | 521 | 570 |
| Current portion of lease liabilities - operating | 2,126 | 2,100 |
| Total current liabilities | 30,823 | 22,846 |
| Non-current liabilities | ||
| Non-current portion of lease liabilities - finance | 698 | 817 |
| Non-current portion of lease liabilities - operating | 6,054 | 6,437 |
| Total liabilities | 37,575 | 30,100 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Common stock, $0.0001 par value, 500,000,000 shares authorized as of March 31, 2025; 33,196,997 shares issued and 33,191,865 shares outstanding as of March 31, 2025; 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024 | 3 | 3 |
| Treasury stock, at cost, 3,827 common shares as of March 31, 2025 and as of December 31, 2024 | (17) | (17) |
| Additional paid-in capital | 401,012 | 397,132 |
| Accumulated other comprehensive loss | (54) | (103) |
| Accumulated deficit | (312,829) | (280,173) |
| Total stockholders' equity | 88,115 | 116,842 |
| Total liabilities and stockholders' equity | $125,690 | $146,942 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.